Lipocine (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing oral delivery solutions for endocrine and metabolic disorders, reported a net loss of $2.4 million for the fourth quarter on Tuesday.
The results come as the Salt Lake City-based firm advances its clinical programs, including its lead candidate for essential tremor and post-acute withdrawal syndrome.
On a per-share basis, Lipocine posted a loss of 34 cents for the three-month period.
Revenue for the quarter was reported at $1.1 million, largely driven by licensing agreements and milestone-related activities.
The company’s financial performance reflects its current stage as a development-heavy entity, where high research and development (R&D) costs often precede commercial scaling.
For the full year 2025, Lipocine reported a total net loss of $9.6 million, or $1.69 per share.
Annual revenue reached $2 million.
Despite the bottom-line deficit, the company has maintained a lean operating structure while seeking strategic partnerships to fund its late-stage clinical trials.